Cal 1-transduced haematopoietic stem progenitor cells

Drug Profile

Cal 1-transduced haematopoietic stem progenitor cells

Alternative Names: Cal 1 therapy; Cal 1-modified HSPC; Cal-1; LVsh5C46; LVsh5C46-transduced-HSPC

Latest Information Update: 22 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Calimmune
  • Class Cell therapies; Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II HIV-1 infections

Most Recent Events

  • 13 Sep 2017 Calimmune withdraws a phase I/II trial prior to enrolment due to participant recruitment difficulties for HIV-1 infections in Australia and USA (ACTRN12615000763549)
  • 14 Oct 2016 Preclinical trials in HIV-1 infections (Prevention) in USA (IV) before October 2016
  • 06 Sep 2016 Calimmune suspends enrolment in a phase I/II trial for HIV-1 infections in Australia (ACTRN12615000763549)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top